Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trimetazidine for cardiac function in adults with cyanotic congenital heart disease and hypoxia
ChiCTR2300074471Phase 4Not yet recruiting
- Sponsor
- Shanghai Children's Medical Center
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of trimetazidine in Cyanotic heart disease (CCHD) (2 arms), sponsored by Shanghai Children's Medical Center. Primary endpoint: Left ventricular ejection fraction. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
trimetazidine
03
Conditions
Cyanotic heart disease (CCHD)
Beyond the preview
Go deeper on ChiCTR2300074471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074471.